Evidence map›Paper›PMID 34426610›Full record

ArticleScientific reports2021

SCAMP2/5 as diagnostic and prognostic markers for acute myeloid leukemia.

Can Yue, Siting Xie, Jiaying Zhong, Haijun Zhao, Zhijuan Lin, Li Zhang, Bing Xu, Yiming Luo

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Can Yue *Graduate College of Fujian Medical University, Fuzhou, 350108, Fujian, People's Republic of China.
Siting Xie *Department of Hematology, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, No. 55 ZhenHai Road, Si Ming District, Xiamen, 361003, Fujian, People's Republic of China.
Jiaying ZhongOrgan Transplantation Institute of Xiamen University, Fujian Provincial Key Laboratory of Organ and Tissue Regeneration, School of Medicine, Xiamen University, Xiamen, 361003, Fujian, People's Republic of China.
Haijun ZhaoDepartment of Hematology, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, No. 55 ZhenHai Road, Si Ming District, Xiamen, 361003, Fujian, People's Republic of China.
Zhijuan LinDepartment of Hematology, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, No. 55 ZhenHai Road, Si Ming District, Xiamen, 361003, Fujian, People's Republic of China.
Li ZhangDepartment of Hematology, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, No. 55 ZhenHai Road, Si Ming District, Xiamen, 361003, Fujian, People's Republic of China.
Bing XuDepartment of Hematology, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, No. 55 ZhenHai Road, Si Ming District, Xiamen, 361003, Fujian, People's Republic of China. xubingzhangjian@126.com.
Yiming LuoDepartment of Hematology, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, No. 55 ZhenHai Road, Si Ming District, Xiamen, 361003, Fujian, People's Republic of China. luoyimingxm@126.com.
Fujian Medical University · CNFirst Affiliated Hospital of Xiamen University · CNXiamen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The secretory carrier-associated membrane proteins (SCAMPs) are associated with the development of multiple human cancers. The role of SCAMPs in acute myeloid leukemia (AML), however, remains to be identified. In the present study, we explored expression patterns and prognostic value of SCAMPs and network analysis of SCAMPs-related signaling pathways in AML using Oncomine, GEPIA, cBioPortal, LinkedOmics, DAVID and Metascape databases. Genetic alteration analysis revealed that the mutation rate of SCAMP genes was below 1% (9/1272) in AML, and there was no significant correlation between SCAMPs gene mutation and AML prognosis. However, the SCAMP2/5 mRNA levels were significantly higher in AML patients than in healthy controls. Moreover, high mRNA expressions of SCAMP2/4/5 were associated with poor overall survival, which might be due to that SCAMP2/4/5 and their co-expressed genes were associated with multiple pathways related to tumorigenesis and progression, including human T-cell leukemia virus 1 infection, acute myeloid leukemia, mTOR and NF-kappa B signaling pathways. These results suggest that SCAMP2/4/5 are potential prognostic markers for AML, and that SCAMP2 and SCAMP5 individually or in combination may be used as diagnostic markers for AML.

Indexed as

Biomarkers, TumorCarrier ProteinsGene Expression Regulation, LeukemicGene OntologyHumansLeukemia, Myeloid, AcuteMembrane ProteinsMutationPrognosisProtein Interaction MapsRNA, MessengerBiomarkers, TumorCarrier ProteinsMembrane ProteinsRNA, MessengerSCAMP2 protein, humanSCAMP5 protein, human

Identifiers

PMID34426610
PMCPMC8382833
OpenAlexW3194190003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.